175 related articles for article (PubMed ID: 30454871)
1. Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease.
Rashidi A; Shanley R; Holtan SG; MacMillan ML; Blazar BR; Khoruts A; Weisdorf DJ
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2190-2196. PubMed ID: 30454871
[TBL] [Abstract][Full Text] [Related]
2. Citrulline and Monocyte-Derived Macrophage Reactivity before Conditioning Predict Acute Graft-versus-Host Disease.
Hueso T; Coiteux V; Joncquel Chevalier Curt M; Labreuche J; Jouault T; Yakoub-Agha I; Seguy D
Biol Blood Marrow Transplant; 2017 Jun; 23(6):913-921. PubMed ID: 28263922
[TBL] [Abstract][Full Text] [Related]
3. Pretransplant β2-Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant.
Costa-Lima C; Miranda ECM; Colella MP; Aranha FJP; de Souza CA; Vigorito AC; De Paula EV
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1329-1332. PubMed ID: 27044906
[TBL] [Abstract][Full Text] [Related]
4. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
5. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U; Fuchs EJ; Bolaños-Meade J; Ghosh N; Herrera AF; Hossain NM; Inwards D; Kanate AS; Martino R; Munshi PN; Murthy H; Mussetti A; Nieto Y; Perales MA; Romee R; Savani BN; Seo S; Wirk B; Yared JA; Sureda A; Fenske TS; Hamadani M
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1859-1868. PubMed ID: 31132455
[TBL] [Abstract][Full Text] [Related]
6. Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.
Rashidi A; DiPersio JF; Westervelt P; Abboud CN; Schroeder MA; Cashen AF; Pusic I; Romee R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1137-1141. PubMed ID: 26988741
[TBL] [Abstract][Full Text] [Related]
7. Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.
Hueso T; Gauthier J; Joncquel Chevalier-Curt M; Magro L; Coiteux V; Dulery R; Carpentier B; Labreuche J; Damaj G; Yakoub-Agha I; Seguy D
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):908-917.e2. PubMed ID: 29258901
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.
McCarthy PL; Attwood KM; Liu X; Chen GL; Minderman H; Alousi A; Bashey A; Lowsky R; Miklos DB; Hansen J; Westervelt P; Yanik G; Waller EK; Howard A; Blazar BR; Wallace PK; Reshef R; Horowitz MM; Maziarz RT; Levine JE; Mohammadpour H
Bone Marrow Transplant; 2024 Mar; 59(3):334-343. PubMed ID: 38110620
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation.
Gjærde LK; Ostrowski SR; Jørgensen NR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transpl Immunol; 2022 Oct; 74():101650. PubMed ID: 35718288
[TBL] [Abstract][Full Text] [Related]
14. Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation.
Pedraza A; Salas MQ; Rodríguez-Lobato LG; Escribano-Serrat S; Suárez-Lledo M; Martínez-Cebrian N; Solano MT; Arcarons J; Rosiñol L; Gutiérrez-García G; Fernández-Avilés F; Moreno-Castaño AB; Molina P; Pino M; Carreras E; Díaz-Ricart M; Rovira M; Palomo M; Martínez C
Transplant Cell Ther; 2024 Feb; 30(2):187.e1-187.e12. PubMed ID: 38000709
[TBL] [Abstract][Full Text] [Related]
15. Platelet and Red Blood Cell Transfusions and Risk of Acute Graft-versus-Host Disease after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Sørensen ALT; von Stemann JH; Fischer-Nielsen A; Hansen MB; Sengeløv H; Ostrowski SR
Transplant Cell Ther; 2021 Oct; 27(10):866.e1-866.e9. PubMed ID: 34252580
[TBL] [Abstract][Full Text] [Related]
16. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
17. A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease.
Bäuerlein CA; Qureischi M; Mokhtari Z; Tabares P; Brede C; Jordán Garrote AL; Riedel SS; Chopra M; Reu S; Mottok A; Arellano-Viera E; Graf C; Kurzwart M; Schmiedgen K; Einsele H; Wölfl M; Schlegel PG; Beilhack A
Front Immunol; 2020; 11():593321. PubMed ID: 33584657
[TBL] [Abstract][Full Text] [Related]
18. Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.
Rezvani AR; Storer BE; Storb RF; Mielcarek M; Maloney DG; Sandmaier BM; Martin PJ; McDonald GB
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1594-601. PubMed ID: 21806949
[TBL] [Abstract][Full Text] [Related]
19. Serum citrulline levels as a marker of enterocyte function in patients after allogeneic hematopoietic stem cells transplantation - a pilot study.
Vokurka S; Svoboda T; Rajdl D; Sedláčková T; Racek J; Koza V; Trefil L
Med Sci Monit; 2013 Feb; 19():81-5. PubMed ID: 23369891
[TBL] [Abstract][Full Text] [Related]
20. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
